Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Honecker, F; Rohlfing, T; Harder, S; Braig, M; Gillis, A J; Glaesener, S; Barett, C; Bokemeyer, C; Buck, F; Brümmendorf, T H; Looijenga, L H; Balabanov, S (2014). Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. Journal of Proteomics, 96:300-313.

Braig, M; Pällmann, N; Preukschas, M; Steinemann, D; Hofmann, W; Gompf, A; Streichert, T; Braunschweig, T; Copland, M; Rudolph, K L; Bokemeyer, C; Koschmieder, S; Schuppert, A; Balabanov, S; Brümmendorf, T H (2014). A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia, 28(10):2028-2039.

Balabanov, S; Braig, M; Brümmendorf, T H (2014). Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discovery Today: Technologies, 11:89-99.

Sievert, H; Pällmann, N; Miller, K K; Hermanns-Borgmeyer, I; Venz, S; Sendoel, A; Preukschas, M; Schweizer, M; Boettcher, S; Janiesch, P C; Streichert, T; Walther, R; Hengartner, M O; Manz, M G; Brümmendorf, T H; Bokemeyer, C; Braig, M; Hauber, J; Duncan, K E; Balabanov, S (2014). A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformation. Disease Models & Mechanisms, 7(8):963-976.

Balabanov, S; Wilhelm, T; Venz, S; Keller, G; Scharf, C; Pospisil, H; Braig, M; Barett, C; Bokemeyer, C; Walther, R; Brümmendorf, T H; Schuppert, A (2013). Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors. PLoS ONE, 8(1):e53668.

Ziegler, P; Chahoud, T; Wilhelm, T; Pällmann, N; Braig, M; Wiehle, V; Ziegler, S; Schröder, M; Meier, C; Kolodzik, A; Rarey, M; Panse, J; Hauber, J; Balabanov, S; Brümmendorf, T H (2012). Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias. Investigational New Drugs, 30(6):2274-2283.

Sievert, H; Venz, S; Platas-Barradas, O; Dhople, V M; Schaletzky, M; Nagel, C H; Braig, M; Preukschas, M; Pällmann, N; Bokemeyer, C; Brümmendorf, T H; Pörtner, R; Walther, R; Duncan, K E; Hauber, J; Balabanov, S (2012). Protein-protein-interaction network organization of the hypusine modification system. Molecular & Cellular Proteomics, 11(11):1289-1305.

Preukschas, M; Hagel, C; Schulte, A; Weber, K; Lamszus, K; Sievert, H; Pällmann, N; Bokemeyer, C; Hauber, J; Braig, M; Balabanov, S (2012). Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. PLoS ONE, 7(8):43468.

This list was generated on Fri Sep 21 01:04:12 2018 CEST.